Povetacicept

4 trials 4 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

4 Recruiting

0 Completed trials

2 Sponsors

19 Countries

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 1 Phase II: 2

Indications tested

Myasthenia gravis 1 Nephropathy 1

Sponsors using this IMP

Alpine Immune Sciences Inc. 2 Vertex Pharmaceuticals Inc. 2

All trials

4 total

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Recruiting

2025-523950-15-01 Phase II 1 country Vertex Pharmaceuticals Inc.
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting

2024-514135-17-00 Phase III 19 countries Alpine Immune Sciences Inc.
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4) Recruiting

2023-507067-19-00 Phase II 5 countries Alpine Immune Sciences Inc.
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Subjects With Primary Membranous Nephropathy Recruiting

2025-521661-27-00 Phase II/III 7 countries Vertex Pharmaceuticals Inc.

Showing 1–4 of 4 trials

← All drugs A–Z